BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lazaros G, Antonatou K, Vassilopoulos D. The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges. Front Med (Lausanne) 2017;4:78. [PMID: 28660191 DOI: 10.3389/fmed.2017.00078] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Malcova H, Milota T, Strizova Z, Cebecauerova D, Striz I, Sediva A, Horvath R. Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now? Front Pharmacol 2020;11:619273. [PMID: 33708123 DOI: 10.3389/fphar.2020.619273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lazaros G, Antonopoulos A, Antoniades C, Tousoulis D. The Role of Epicardial Fat in Pericardial Diseases. Curr Cardiol Rep 2018;20. [DOI: 10.1007/s11886-018-0986-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Dagan A, Langevitz P, Shoenfeld Y, Shovman O. Anakinra in idiopathic recurrent pericarditis refractory to immunosuppressive therapy; a preliminary experience in seven patients. Autoimmunity Reviews 2019;18:627-31. [DOI: 10.1016/j.autrev.2019.01.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
4 Emmi G, Urban ML, Imazio M, Gattorno M, Maestroni S, Lopalco G, Cantarini L, Prisco D, Brucato A. Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. Curr Cardiol Rep 2018;20:61. [PMID: 29904899 DOI: 10.1007/s11886-018-1007-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
5 Gupta M, Kaul S, Velazquez GR, Bandyopadhyay D, Fonarow GC, Klein A, Ghosh RK. A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option. Am J Cardiovasc Drugs 2022;22:27-33. [PMID: 34008144 DOI: 10.1007/s40256-021-00481-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Vecchié A, Del Buono MG, Mauro AG, Cremer PC, Imazio M, Klein AL, Abbate A, Dentali F, Bonaventura A. Advances in pharmacotherapy for acute and recurrent pericarditis. Expert Opinion on Pharmacotherapy. [DOI: 10.1080/14656566.2022.2054327] [Reference Citation Analysis]
7 Brucato A, Emmi G, Cantarini L, Di Lenarda A, Gattorno M, Lopalco G, Marcolongo R, Imazio M, Martini A, Prisco D. Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Intern Emerg Med 2018;13:475-89. [DOI: 10.1007/s11739-018-1842-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
8 Maniscalco V, Abu-Rumeileh S, Mastrolia MV, Marrani E, Maccora I, Pagnini I, Simonini G. The off-label use of anakinra in pediatric systemic autoinflammatory diseases. Ther Adv Musculoskelet Dis 2020;12:1759720X20959575. [PMID: 33149772 DOI: 10.1177/1759720X20959575] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Lazaros G, Tousoulis D, Vassilopoulos D. Editorial commentary: Recurrent pericarditis in the era of interleukin-1 inhibition. Trends Cardiovasc Med 2021;31:275-6. [PMID: 32417368 DOI: 10.1016/j.tcm.2020.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Lazaros G, Lazarou E, Tsioufis P, Soulaidopoulos S, Iliakis P, Vlachopoulos C, Tsioufis C. Chronic pericardial effusion: current concepts and emerging trends. Expert Rev Cardiovasc Ther 2022. [PMID: 35524164 DOI: 10.1080/14779072.2022.2075346] [Reference Citation Analysis]
11 Lazaros G, Tousoulis D. Interleukin-1 inhibition with anakinra: a valuable ally to reverse constrictive pericarditis? Heart 2020;106:1540-2. [DOI: 10.1136/heartjnl-2020-317187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Lazarou E, Lazaros G, Antonopoulos AS, Imazio M, Vasileiou P, Karavidas A, Toutouzas K, Vassilopoulos D, Tsioufis C, Tousoulis D, Vlachopoulos C. A risk score for pericarditis recurrence. Eur J Clin Invest 2021;:e13602. [PMID: 34050527 DOI: 10.1111/eci.13602] [Reference Citation Analysis]
13 Khazim K, Azulay EE, Kristal B, Cohen I. Interleukin 1 gene polymorphism and susceptibility to disease. Immunol Rev 2018;281:40-56. [DOI: 10.1111/imr.12620] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
14 Lazarou E, Tsioufis P, Vlachopoulos C, Tsioufis C, Lazaros G. Acute Pericarditis: Update. Curr Cardiol Rep 2022. [PMID: 35595949 DOI: 10.1007/s11886-022-01710-8] [Reference Citation Analysis]
15 Tombetti E, Mulè A, Tamanini S, Matteucci L, Negro E, Brucato A, Carnovale C. Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020. Curr Cardiol Rep 2020;22:59. [PMID: 32562029 DOI: 10.1007/s11886-020-01308-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
16 Correia ETO, Dos Santos Barbetta LM, de Almeida JPCL, Mesquita ET. Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety. J Cardiovasc Pharmacol 2020;76:42-9. [PMID: 32265370 DOI: 10.1097/FJC.0000000000000839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Avondo S, Andreis A, Casula M, Biondi-Zoccai G, Imazio M. Pharmacologic treatment of acute and recurrent pericarditis: a systematic review and meta-analysis of controlled clinical trials. Panminerva Med 2021;63:314-23. [PMID: 34738773 DOI: 10.23736/S0031-0808.21.04263-4] [Reference Citation Analysis]
18 Lasrado N, Yalaka B, Reddy J. Triggers of Inflammatory Heart Disease. Front Cell Dev Biol 2020;8:192. [PMID: 32266270 DOI: 10.3389/fcell.2020.00192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Fava AM, Reyaldeen R, Lo Presti S, Goyal A, Akintoye E, Hughes D, Klein AL. Rilonacept for the treatment of recurrent pericarditis. Expert Opin Biol Ther 2021. [PMID: 34757872 DOI: 10.1080/14712598.2022.2005024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Andreis A, Imazio M, de Ferrari GM. Contemporary diagnosis and treatment of recurrent pericarditis. Expert Review of Cardiovascular Therapy 2019;17:817-26. [DOI: 10.1080/14779072.2019.1691916] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Rodriguez-Gonzalez M, Ruiz-Gonzalez E, Castellano-Martinez A. Anakinra as rescue therapy for steroid-dependent idiopathic recurrent pericarditis in children: case report and literature review. Cardiol Young 2019;29:241-3. [PMID: 30511600 DOI: 10.1017/S1047951118002020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Lazaros G, Antonopoulos AS, Antonatou K, Skendros P, Ritis K, Hadziyannis E, Lazarou E, Leontsinis I, Simantiris S, Vlachopoulos C, Tousoulis D, Vassilopoulos D. Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: A pilot observational prospective study. International Journal of Cardiology 2020;311:77-82. [DOI: 10.1016/j.ijcard.2020.03.069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Epçaçan S, Sahin S, Kasapcopur O. Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab. Cardiol Young 2019;29:549-51. [DOI: 10.1017/s1047951119000672] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
24 Bizzi E, Trotta L, Pancrazi M, Nivuori M, Giosia V, Matteucci L, Montori D, Brucato A. Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments. Curr Cardiol Rep 2021;23:128. [PMID: 34319478 DOI: 10.1007/s11886-021-01549-5] [Reference Citation Analysis]
25 Gerardin C, Mageau A, Benali K, Jouan F, Ducrocq G, Alexandra JF, van Gysel D, Papo T, Sacre K. Increased FDG-PET/CT pericardial uptake identifies acute pericarditis patients at high risk for relapse. Int J Cardiol 2018;271:192-4. [PMID: 29884293 DOI: 10.1016/j.ijcard.2018.05.126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
26 Andreis A, Imazio M, Giustetto C, Brucato A, Adler Y, De Ferrari GM. Anakinra for constrictive pericarditis associated with incessant or recurrent pericarditis. Heart 2020;106:1561-5. [DOI: 10.1136/heartjnl-2020-316898] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]